Bausch Health Companies Inc.

10:58 AM EST - Bausch Health Companies Inc. : And Allegro Ophthalmics, LLC (Allegro), a privately held biopharmaceutical company focused on the development of novel therapies that regulate integrin functions for the treatment of ocular diseases, announced today that Bausch Health (through its affiliate) has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro (the "Option"), including global rights for risuteganib (Luminate®) , Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration. Bausch Health Companies Inc. shares T.BHC are trading down $1.09 at $21.63.